APEX1 and eye disorder: Because APE1/Ref-1 simultaneously affects angiogenesis, inflammation, stress response and other key pathways implicated in neovascular eye disease, targeting APE1/Ref-1 may be a novel approach that has the potential to improve disease outcomes in many patients and may be a better therapeutic tactic than current anti-VEGF therapies.